Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Common Equity (2019 - 2025)

Historic Common Equity for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$1.7 million.

  • Biodesix's Common Equity fell 10618.16% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 10618.16%. This contributed to the annual value of $20.9 million for FY2024, which is 35580.79% up from last year.
  • Per Biodesix's latest filing, its Common Equity stood at -$1.7 million for Q3 2025, which was down 10618.16% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Common Equity ranged from a high of $36.4 million in Q1 2021 and a low of -$7.0 million during Q2 2023
  • Its 5-year average for Common Equity is $11.7 million, with a median of $7.8 million in 2022.
  • The largest annual percentage gain for Biodesix's Common Equity in the last 5 years was 202648.69% (2024), contrasted with its biggest fall of 22092.31% (2024).
  • Over the past 5 years, Biodesix's Common Equity (Quarter) stood at $19.7 million in 2021, then rose by 4.46% to $20.6 million in 2022, then crashed by 77.77% to $4.6 million in 2023, then skyrocketed by 355.81% to $20.9 million in 2024, then plummeted by 108.25% to -$1.7 million in 2025.
  • Its Common Equity stands at -$1.7 million for Q3 2025, versus $1.1 million for Q2 2025 and $11.1 million for Q1 2025.